Publications

  1. Pophali PA, Larson MC, Rosenthal AC, Robinson D, Habermann TM, Thanarajasingam G, Call T, Allmer C, Farooq U, Maurer MJ, Yost KJ, Cerhan JR, Thompson CA. The association of health behaviors with quality of life in lymphoma survivors. Leuk Lymphoma. 2020 Oct 13; 1-10 [Epub ahead of print]
    View PubMed
  2. Hwang SR, Higgins A, Castillo Almeida NE, LaPlant B, Maurer MJ, Ansell SM, Witzig TE, Thanarajasingam G, Bennani NN. Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. Leuk Lymphoma. 2020 Oct 6; 1-5 Epub 2020 Oct 06
    View PubMed
  3. Pophali PA, Thanarajasingam G. Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020 Oct; 34 (5):971-982 Epub 2020 Aug 05
    View PubMed
  4. Wong ML, Gao J, Thanarajasingam G, Sloan JA, Dueck AC, Novotny PJ, Jatoi A, Hurria A, Walter LC, Miaskowski C, Cohen HJ, Wood WA, Feliciano JL, Stinchcombe TE, Wang X. Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729). Oncologist. 2020 Sep 20 Epub 2020 Sept 20
    View PubMed
  5. Drago JZ, Gonen M, Thanarajasingam G, Sacks CA, Morris MJ, Kantoff PW, Stopsack KH. Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer. J Natl Cancer Inst. 2020 Aug 28 [Epub ahead of print]
    View PubMed
  6. Thanarajasingam G, Leonard JP, Witzig TE, Habermann TM, Blum KA, Bartlett NL, Flowers CR, Pitcher BN, Jung SH, Atherton PJ, Tan A, Novotny PJ, Dueck AC. Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Lancet Haematol. 2020 Jun; 7 (6):e490-e497
    View PubMed
  7. Jakobsen LH, Ellin F, Smeland KB, Wasterlid T, Christensen JH, Jorgensen JM, Josefsson PL, Ovlisen AK, Holte H, Blaker YN, Grauslund JH, Bjorn J, Molin D, Lagerlof I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. Br J Haematol. 2020 May; 189 (4):661-671 Epub 2020 Feb 04
    View PubMed
  8. St-Pierre F, Broski SM, LaPlant BR, Maurer MJ, Ristow K, Thanarajasingam G, Macon WR, Habermann TM, Witzig TE. Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. Oncologist. 2020 Apr 22 [Epub ahead of print]
    View PubMed
  9. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P. Impact of MYD88(L265P) mutation status on histological transformation of Waldenstrom Macroglobulinemia. Am J Hematol. 2020 Mar; 95 (3):274-281 Epub 2019 Dec 31
    View PubMed
  10. Atkinson TM, Dueck AC, Satele DV, Thanarajasingam G, Lafky JM, Sloan JA, Basch E. Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials. JAMA Oncol. 2020 Mar 1; 6 (3):437-439
    View PubMed
  11. Dueck AC, Scher HI, Bennett AV, Mazza GL, Thanarajasingam G, Schwab G, Weitzman AL, Rogak LJ, Basch E. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. JAMA Oncol. 2020 Feb 1; 6 (2):e193332 Epub 2020 Feb 13
    View PubMed
  12. Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS, Mayo Clinic Histiocytosis Working Group. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020; 105 (2):348-357 Epub 2020 Jan 31
    View PubMed
  13. Marshall AL, Dines V, Wahner Hendrickson A, Warsame R, Thanarajasingam G, Thompson C, Petterson T, Wolanskyj-Spinner A. Parental health in fellowship trainees: Fellows' satisfaction with current policies and interest in innovation. Womens Health (Lond). 2020 Jan-Dec; 16:1745506520949417
    View PubMed
  14. Viscuse P, Yost KJ, Jenkins S, Lackore K, Habermann T, Thanarajasingam G, Thompson C. Impact of lymphoma survivorship clinic visit on patient-centered outcomes. J Cancer Surviv. 2019 Jun; 13 (3):344-352 Epub 2019 Apr 26
    View PubMed
  15. Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018 Nov; 5 (11):e563-e598 Epub 2018 June 18
    View PubMed
  16. Marinelli JP, Modzeski MC, Lane JI, Van Gompel JJ, Stokken JK, Thanarajasingam G, Carlson ML. Primary Skull Base Lymphoma: Manifestations and Clinical Outcomes of a Great Imitator. Otolaryngol Head Neck Surg. 2018 Oct; 159 (4):643-649 Epub 2018 May 08
    View PubMed
  17. Thanarajasingam G, Maurer MJ, Habermann TM, Nowakowski GS, Bennani NN, Thompson CA, Cerhan JR, Witzig TE. Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker? Nutr Cancer. 2018 Oct; 70 (7):1088-1090 Epub 2018 Sept 20
    View PubMed
  18. Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS. Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 2018 Oct; 183 (1):149-152 Epub 2017 Sept 29
    View PubMed
  19. Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value Health. 2018 Jun; 21 (6):742-747 Epub 2017 Nov 07
    View PubMed
  20. El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018 Apr; 93:57-68 Epub 2018 Feb 21
    View PubMed
  21. Farooq U, Maurer MJ, Thompson CA, Thanarajasingam G, Inwards DJ, Micallef I, Macon W, Syrbu S, Lin T, Lin Y, Ansell SM, Nowakowski GS, Habermann TM, Cerhan JR, Link BK. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. Br J Haematol. 2017 Oct; 179 (1):50-60 Epub 2017 June 27
    View PubMed
  22. Hamadah AM, Thanarajasingam G, Gharaibeh KA, Finnes HD, Thompson CA, Leung N. Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis. Leuk Lymphoma 2017 Feb; 58 (2):457-460 Epub 2016 June 07
    View PubMed
  23. Botero JP, Thanarajasingam G, Warsame R. Capturing and Incorporating Patient-Reported Outcomes into Clinical Trials: Practical Considerations for Clinicians. Curr Oncol Rep. 2016 Oct; 18 (10):61
    View PubMed
  24. Thanarajasingam G, Thanarajasingam U, Ansell SM. Immune checkpoint blockade in lymphoid malignancies. FEBS J. 2016 Jun; 283 (12):2233-44 Epub 2016 Feb 22
    View PubMed
  25. Bennani-Baiti N, Thanarajasingam G, Ansell S. Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma. Expert Rev Clin Immunol. 2016 Jun; 12: (6)673-9.
    View PubMed
  26. Thanarajasingam G, Atherton PJ, Novotny PJ, Loprinzi CL, Sloan JA, Grothey A. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol. 2016 May; 17 (5):663-70 Epub 2016 Apr 12
    View PubMed
  27. Thanarajasingam G, Bennani-Baiti N, Thompson CA. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma. Curr Treat Options Oncol. 2016 May; 17 (5):24
    View PubMed
  28. Thanarajasingam G, Bennani NN, Nowakowski GS. Individualized Treatment of Diffuse Large B-cell Lymphoma— The Evolving Role of Molecular-subtype-specific Therapy Oncology & Hematology Review.2015 Nov 2;11:(2):113-4.
  29. Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A. The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. J Natl Cancer Inst. 2015 Oct; 107: (10).
    View PubMed
  30. Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler C, Nikiforow S, Ho VT, Koreth J, Alyea EP, Soiffer RJ. Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep; 100 (9):1222-7 Epub 2015 June 18
    View PubMed
  31. Thanarajasingam G, Milone M, Kohli M. Paraneoplastic encephalopathy: an unusual presenting feature of bladder cancer metastasis. BMJ Case Rep. 2015 May 4; 2015 Epub 2015 May 04
    View PubMed
  32. Kasi PM, Thanarajasingam G, Finnes HD, Villasboas Bisneto JC, Hubbard JM, Grothey A. Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. Case Rep Oncol Med. 2015; 2015:420159 Epub 2015 May 21
    View PubMed
  33. Barton DL, Thanarajasingam G, Sloan JA, Diekmann B, Fuloria J, Kottschade LA, Lyss AP, Jaslowski AJ, Mazurczak MA, Blair SC, Terstriep S, Loprinzi CL. Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer. 2014 Nov 15; 120 (22):3575-83 Epub 2014 July 09
    View PubMed
  34. Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Armand P. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Dec; 19 (12):1713-8 Epub 2013 Sept 27
    View PubMed
  35. Thanarajasingam G, Vaidya R, Erie A, Wolanskyj AP. Accessory splenectomy for refractory immune thrombocytopenic purpura. Am J Hematol. 2011 Jun; 86(6):520-3. Epub 2011 Apr 25.
    View PubMed
  36. Palmer SR, Thanarajasingam G, Wolanskyj AP. 39-year-old woman with an obscure case of anemia. Mayo Clin Proc. 2010 Jan; 85 (1):e1-4
    View PubMed
  37. Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R, Wolanskyj AP. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol. 2009 Jul; 83(1):17-21. Epub 2009 Feb 19.
    View PubMed
  38. Melin G, Somers K, Thanarajasingam G, Couser G, Reese M. A Reverend's Tale: Too Tragic to be True? Current Psychiatry. 2008 May; 7(5):110-2.
  39. Abizaid A, Mezei G, Thanarajasingam G, Horvath TL. Estrogen enhances light-induced activation of dorsal raphe serotonergic neurons. Eur J Neurosci. 2005 Mar; 21: (6)1536-46.
    View PubMed